OBJECTIVE -The relationships between iron metabolism and type 2 diabetes are bidirectional: iron affects glucose metabolism and glucose metabolism impinges on several iron metabolic pathways. The mechanisms of these interactions depend on poorly known factors. We aimed to study the contribution of the serum soluble transferrin receptor (sTfR).
I
nsulin is an anabolic hormone that stimulates the cellular uptake of many nutrients, including hexoses, amino acids, cations, and anions. In the steady state, iron circulates bound to transferrin and is taken up from the blood by a highaffinity specific transferrin receptor (TfR) (1) . The TfR complex is internalized by endocytosis and released into a nonacidic cellular compartment, where it can be used in the synthesis of essential cellular components. Insulin is known to cause a rapid and marked stimulation of iron uptake by fat cells, redistributing TfRs from an intracellular membrane compartment to the cell surface (2) . Insulin also induces iron transport and accumulation in hepatocytes by a similar mechanism (2) and is responsible for increased ferritin synthesis in cultured rat glioma cells (3) . TfRs have been shown to colocalize with insulin-responsive glucose transporters and IGF-II receptors in the microsomal membranes of cultured adipocytes, suggesting that regulation of iron uptake by insulin parallels its effects on glucose transport (4) .
The synthesis of TfR and the iron storage protein ferritin is regulated reciprocally at the posttranscriptional level according to the cellular iron status (5) . As a result of the externalization of TfR during the endocytic cycle, a soluble form of TfR can be detected in serum (serum TfR [sTfR] ). Circulating sTfR concentrations are proportional to cellular expression of the membrane-associated TfR (6) . sTfR concentration is closely related to cellular iron demands; hence, the higher the ferritin level, the lower the sTfR concentration.
In a recent study, increased serum ferritin levels were found in type 2 diabetic patients in the absence of a reciprocal decrease of sTfR (7) . This finding suggested to the authors that elevated ferritin levels in type 2 diabetes was due to inflammatory mechanisms rather than iron overload. However, they also observed higher sTfR levels in type 2 diabetic patients treated with insulin than in those treated with oral agents (7).
These observations are important because emerging scientific evidence has disclosed unsuspected influences between iron metabolism and type 2 diabetes (8) . Increased iron stores have been found to predict the development of type 2 diabetes, whereas iron depletion seems protective. The mechanisms of these interactions depend on poorly known factors (8) .
Thus, the aim of this study was to evaluate the possible associations among insulin resistance, insulin secretion, metabolic variables, and serum sTfR concentration after controlling for iron status.
RESEARCH DESIGN AND
METHODS -A total of 221 Caucasian men were recruited and studied. There were 153 of them recruited in an ongoing study dealing with nonclassical cardiovascular risk factors in Northern
Spain. Subjects were randomly localized from a census and were invited to participate. The participation rate was 71%. A 75-g oral glucose tolerance test (OGTT) according to the American Diabetes Association criteria was performed in all subjects. All subjects with normal glucose tolerance (NGT) (n ϭ 97) had fasting plasma glucose Ͻ7.0 mmol/l and 2-h postload plasma glucose Ͻ7.8 mmol/l after a 75-g OGTT. Impaired glucose tolerance (IGT) was diagnosed in 36 subjects according to the American Diabetes Association criteria (postload glucose between 7.8 and 11.1 mmol/l). Previously unknown type 2 diabetes was diagnosed in 20 of these 153 subjects (postload glucose Ͼ11.1 mmol/l). Inclusion criteria were 1) BMI Ͻ40 kg/m 2 , 2) absence of systemic disease, 3) absence of infection within the previous month, and 4) serum ferritin Ͼ10 ng/ml and normal blood hemoglobin concentration (Ͼ12 g/dl) to exclude iron deficiency. None of the control subjects were under medication or had evidence of metabolic disease other than obesity. Alcohol and caffeine were withheld within 12 h of performing the insulin sensitivity test. Smokers were defined as any person consuming at least one cigarette a day in the previous 6 months. Resting blood pressure was measured as previously reported (9 -11) . Liver disease and thyroid dysfunction were specifically excluded by biochemical workup.
To increase the statistical power of the group of patients with type 2 diabetes, 68 patients were prospectively recruited from diabetes outpatient clinics on the basis of a stable metabolic control in the previous 6 months, as defined by stable A1C values. Data from these patients were merged with those from the recently diagnosed type 2 diabetic patients. Exclusion criteria for these patients included the following: 1) clinically significant hepatic, neurological, endocrinologic, or other major systemic disease, including malignancy; 2) history or current clinical evidence of hemochromatosis; 3) history of drug or alcohol abuse, defined as Ͼ80 g/day in men and Ͼ40 g/day in women, or serum transaminase activity more than twice the upper limit of normal; 4) an elevated serum creatinine concentration; 5) acute major cardiovascular event in the previous 6 months; 6) acute illnesses and current evidence of acute or chronic inflammatory or infective diseases; and 7) mental illness rendering the subjects unable to understand the nature, scope, and possible consequences of the study. Pharmacological treatment for these patients was as follows: insulin: 29 patients; metformin: 35 patients; sulfonylureas: 14 patients; statins: 28 patients; fibrates: 9 patients; blood pressure-lowering agents: 32 patients; aspirin: 32 patients; and allopurinol: 3 patients. All subjects gave written informed consent after the purpose of the study was explained to them. The institutional review board of the institution approved the protocol.
Anthropometric and clinical measurements BMI was calculated as weight (in kilograms) divided by height (in meters) squared. The subjects waist was measured with a soft tape midway between the lowest rib and the iliac crest. The hip circumference was measured at the widest part of the gluteal region. The waistto-hip ratio was then calculated.
Study of insulin sensitivity
In those subjects who agreed (60 with NGT, 28 with IGT, and 7 patients with type 2 diabetes), insulin sensitivity was measured using the frequently sampled intravenous glucose tolerance test with minimal model analysis. In brief, the experimental protocol started between 8:00 and 8:30 A.M. after an overnight fast. A butterfly needle was inserted into an antecubital vein, and patency was maintained with a slow saline drip. Basal blood samples were drawn at Ϫ30, Ϫ10, and Ϫ5 min, after which glucose (300 mg/kg body wt) was injected over 1 min starting at time 0, and insulin (0.03 units/kg; Actrapid, Novo, Denmark) was administered at time 20. Additional samples were obtained from a contra-lateral antecubital vein up to 180 min, as previously described (9,10).
Analytical methods
Serum glucose concentrations were measured in duplicate by the glucose oxidase method using a Beckman glucose analyzer II (Beckman Instruments, Brea, CA). Total serum cholesterol was measured through the reaction of cholesterol esterase/cholesterol oxidase/peroxidase. Total serum triglycerides were measured through the reaction of glycerolphosphate-oxidase and peroxidase. A1C was measured by the high-performance liquid chromatography method (Bio-Rad [Muenchen, Germany] and autoanalyzer Jokoh HS-10). Intra-and interassay coefficients of variation were Ͻ4% for all these tests.
Serum insulin levels were measured in duplicate by monoclonal immunoradiometric assay or enzyme-amplified sensitivity immunoassay (Medgenix Diagnostics, Fleunes, Belgium). Intra-and interassay coefficients of variation were similar to those previously reported (9, 10) .
Serum C-reactive protein (ultrasensitive assay; Beckman, Fullerton, CA) was determined by a routine laboratory test, with intra-and interassay coefficients of variation Ͻ4%. The lower limit of detection is 0.02 mg/l.
Serum soluble TfR was measured using a double monoclonal sandwich enz y m e i m m u n o a s s a y ( B i o v e n d o r , Palacheho tr., Brno, Czech Republic). Intra-and interassay coefficients of variation were Ͻ4.5%.
Statistical analysis
Descriptive results of continuous variables are expressed as mean (SD). Before statistical analysis, normal distribution and homogeneity of the variances were evaluated using Levene's test, and then variables were given a base 10 logtransformation if necessary. These parameters (ferritin, C-reactive protein, postload insulin, insulin sensitivity [S I ], and triglycerides) were analyzed on a log scale and tested for significance on that scale. The anti-log-transformed values of the means (geometric mean) are reported in the tables for this article. Relation between variables was tested using Pearson's test (with log-transformed values) and multiple linear regression analysis. We used unpaired t tests and the ANOVA test with Bonferroni's post hoc analysis for comparisons of quantitative variables. General linear model for repeated measures with Bonferroni's correction was used to compare sTfR levels during OGTT. The statistical analyses were performed using the program SPSS (version 12.0).
RESULTS -Characteristics of the subjects and the comparisons among groups are shown in Table 1 . Subjects with IGT or type 2 diabetes were significantly older, were heavier, and showed lower insulin sensitivity than subjects with NGT.
We observed no differences in serum sTfR or ferritin among groups. However, subjects with altered glucose tolerance (i.e., with IGT or type 2 diabetes) showed significantly increased sTfR (9.4 Ϯ 4.4 vs. 8.2 Ϯ 2.6 g/ml, P ϭ 0.02) and increased
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DIABETES CARE, VOLUME 30, NUMBER 3, MARCH 2007serum log ferritin (2.3 Ϯ 0.37 vs. 2.2 Ϯ 0.34, P ϭ 0.04). When considering nonobese subjects separately, IGT subjects showed significantly increased serum sTfR concentration compared with the NGT group (Table 1, legend † †).
Serum sTfR was negatively associated with serum ferritin (r ϭ Ϫ0.16, P ϭ 0.02). Interestingly, sTfR also correlated with several clinical and metabolic variables such as systolic blood pressure, glycated hemoglobin and glucose and insulin values during the OGTT, and Creactive protein ( Table 2 ). The best association was observed with serum glucose and insulin 30Ј after OGTT. However, this latter association was significant in subjects with NGT but not in those with altered glucose tolerance (r ϭ 0.35, P ϭ 0.001, Fig. 1 ). Insulin sensitivity was also negatively associated with sTfR in normal (r ϭ Ϫ0.30, P ϭ 0.02) but not in subjects with altered glucose tolerance. Obesity status also influenced these results. Insulin sensitivity correlated negatively with sTfR in nonobese subjects (r ϭ Ϫ0.49, P Ͻ 0.0001, n ϭ 70), but not in obese subjects (r ϭ Ϫ0.19, P ϭ 0.3). However, probably because of the low number of obese subjects, we could not detect significant differences in the correlation coefficients between obese and nonobese subjects (P ϭ 0.19).
We performed a multiple linear regression analysis to predict circulating sTfR. We considered as independent variables those with significant association on univariant analysis. As shown in supplemental Table S1 (please see the online appendix at http://dx.doi.org/10.2337/ dc06-1138), BMI (P ϭ 0.01), serum ferritin (P ϭ 0.025), and insulin sensitivity (P Ͻ 0.0001) contributed independently to 21% of sTfR variance, after controlling for the effects of age, systolic blood pressure, and serum insulin 30Ј post-OGTT.
Among type 2 diabetic patients, individuals treated with insulin (n ϭ 29) showed a tendency toward increased sTfR concentration (11.4 Ϯ 7.4 vs. 8.5 Ϯ 3.2 g/ml, P ϭ 0.057) and similar log serum ferritin concentrations (2.1 Ϯ 0.5 vs. 2.14 Ϯ 0.4, P ϭ 0.3). Patients treated with sulfonylureas (n ϭ 14) also showed significantly increased sTfR concentrations (9.8 Ϯ 3.4 vs. 7.0 Ϯ 2.7 g/ml, P ϭ 0.02). Patients treated (n ϭ 35) and untreated with metformin showed nonsignificantly different serum sTfR concentrations (9 Ϯ 4.2 vs. 10.1 Ϯ 6 g/ ml, P ϭ 0.2). Four patients were treated with insulin and metformin, and three patients were treated with sulfonylureas and metformin concomitantly. Inclusion or exclusion of these subjects in the analysis did not significantly change the results. Known patients with type 2 diabetes (duration of diabetes 7 Ϯ 3 years), in contrast to newly diagnosed type 2 diabetic patients, had increased A1C values (6.9 Ϯ 1.3 vs. 5.0 Ϯ 0.9, for known and new type 2 diabetic patients, respectively; P Ͻ 0.0001). Duration of diabetes had no significant influence on serum sTfR concentration. When evaluating the relationship between serum sTfR concentration and glycated hemoglobin separately in type 2 diabetic patients, we did not find any significant association (r ϭ 0.15, P ϭ 0.12). However, obesity status and treatment influenced the relationship between sTfR concentration and glycated hemoglobin. These parameters were significantly associated in lean subjects (r ϭ 0.59, P ϭ 0.04, n ϭ 12), in subjects not treated with insulin (r ϭ 0.30, P ϭ 0.02, n ϭ 59), in patients receiving statins (r ϭ 0.49, P ϭ 0.01, n ϭ 28), and in patients receiving aspirin (r ϭ 0.36, P ϭ 0.04, n ϭ 32). In patients receiving insulin or sulfonylureas, these associations were not significant.
Study of acute regulation by insulin
To investigate the possible mechanisms of increased sTfR, we evaluated sTfR during OGTT in eight subjects (aged 55.2 Ϯ 9.2 years, BMI 26.5 Ϯ 1.9 kg/m 2 ). Serum sTfR concentration did not significantly change during the OGTT (sTfR concentration was 10.89 Ϯ 1.9 g/ml at baseline and remained essentially unchanged during the test). In this study, the best association was shown between insulin at 30 min during the OGTT and sTfR at 60 min (r ϭ 0.83, P ϭ 0.01).
CONCLUSIONS -Serum sTfR represents a soluble fragment of the extracellular receptor domain. Extensive previous studies indicate that, if iron deficiency is excluded (as was the case in all subjects studied), the level of serum receptors provides a quantitative measure of total erythropoiesis (6) . TfR is expressed in a limited number of sites-notably immature erythroid cells, Kupffer cells, hepatocytes, testis, the pituitary gland, and the endocrine pancreas (12) . In this article, we provide evidence according to which insulin sensitivity and insulin secretion are important factors influencing serum sTfR concentrations.
Serum sTfR concentrations were associated with acute insulin stimulation during OGTT (insulin levels 30Ј after OGTT). Insulin is known to cause a rapid and marked stimulation of iron uptake by fat cells, redistributing TfRs from an intracellular membrane compartment to the cell surface (2) . TfRs have been shown to colocalize with insulin-responsive glucose transporters in cultured adipocytes, suggesting that regulation of iron uptake by insulin parallels its effects on glucose transport. The effects of insulin increasing TfR have been observed in a myeloid leukemia cell line and mouse mammary gland cells (13) . It has also been demonstrated that insulin injections increase sTfR in rats (14) . Hyperinsulinemia may contribute to the inappropriately high sTfR concentration detected in subjects with altered glucose tolerance.
Serum sTfR concentrations seem not acutely regulated by insulin in humans, given the unaltered serum sTfR levels during the OGTT. This finding hints at a long-term regulation by insulin sensitivity. We cannot exclude, however, acute effects with prolonged insulin infusions. Insulin sensitivity, independently of age, obesity, and iron status, contributed independently to sTfR variance (supplemental Table S1 ). We observed that the lower the insulin sensitivity, the higher the sTfR concentration, but only in subjects with NGT. Thus, subjects with altered glucose tolerance and type 2 diabetic patients not treated with aspirin or statins (see below) have in common some underlying factors that disrupt this relationship. In this sense, we were intrigued for the positive association between C-reactive protein and serum sTfR concentration. Different cytokines upregulate TfR expression in in vitro models (15, 16) . It is possible that different inflammatory factors lead to a spurious increase in serum sTfR in subjects with altered glucose tolerance and that treatment with aspirin or statins correct to some extent this increase.
Our findings are in agreement with those described by Hernández et al. (7), who described increased sTfR concentration in those type 2 diabetic patients treated with insulin. In this study, we also found that those patients treated with insulin or with sulfonylureas had significantly higher sTfR concentration. Furthermore, we found that concomitant treatment also influenced the association between serum sTfR concentration and glycated hemoglobin. Again, a spurious increase in sTfR in patients treated with insulin could obscure the relationship between sTfR and glycated hemoglobin. Although factors related to hyperglycemia or oxidative stress could mediate in part this association, increased A1C may also reflect a more severe insulin resistance (17) . As found in nondiabetic subjects, the relationship between A1C and sTfR was significant in those subjects with less interference with inflammatory factors: lean subjects and patients receiving aspirin or statins.
Other possibilities cannot be excluded. Exposure of newborn rats to hypoxia leads to a significant increase in TfR expression in microglial cells (18) . In fact, the promoter region of the TfR gene contains a hypoxia response element that mediates transcriptional activation by hypoxia-inducible factor 1 (19) . The relative hypoxia-linked hyperglycemia could underlie the increased serum sTfR concentration in states of altered glucose tolerance (20) .
A scenario can be envisioned in which the physiological action of insulin leads to increased uptake of different nutrients and iron. Any factor causing hyperinsulinemia (weight gain, aging, repeated usual-life infections) amplifies this process, determining increased deposition of iron, which in the long term worsens insulin resistance. Once insulin secretion declines, this regulation is lost. At this stage, uptake of excess iron is probably regulated by the reticuloendothelial system.
With the information contained in this article, it will be important to test if serum sTfR concentration is equally useful in evaluating total erythropoiesis in patients with altered glucose tolerance compared with individuals with NGT.
In summary, both insulin sensitivity and insulin secretion are significantly associated with serum sTfR concentrations, although insulin sensitivity independently predicts circulating sTfR, mainly in subjects with NGT. The implications of these interrelationships between iron and glucose metabolism should be investigated further.
